SeekingAlpha · Oct 24, 2026
NYSE · VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
$540.00
Up+$18.88 (+3.50%)
Updated Oct 30, 2026, 10:11 PM
SID Score
6.3/10
Composite research score
Smart Money
48/100
Neutral
- Market cap
- 114.46B
- P/E ratio
- 31.02
- Dividend yield
- 0.00%
- 52-week range
- $412.27 – $560.25
- Volume
- 1.54M
- Avg. volume
- 1.51M
Price performance · VRTX
VRTX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
VRTX closed at $540.00 after 21 trading sessions, up 6.56% for the selected period.
- Last close
- $540.00
- Period change
- +6.56%
- Period low
- $485.22
- Period high
- $540.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $536.46 | $546.61 | $534.01 | $540.00 | 1.54M |
| Oct 28, 2026 | $514.45 | $534.94 | $513.37 | $529.69 | 1.28M |
| Oct 27, 2026 | $514.835 | $521.43 | $509.205 | $521.03 | 1.02M |
| Oct 26, 2026 | $526.86 | $529.66 | $509.33 | $517.49 | 1.19M |
| Oct 23, 2026 | $531.66 | $533.08 | $522.91 | $523.93 | 832.63K |
| Oct 22, 2026 | $527.18 | $537.81 | $521.295 | $535.17 | 1.64M |
| Oct 21, 2026 | $512.79 | $528.57 | $510.48 | $524.52 | 1.45M |
| Oct 20, 2026 | $507.89 | $515.735 | $505.00 | $514.65 | 1.23M |
| Oct 19, 2026 | $500.00 | $505.83 | $499.50 | $501.95 | 1.3M |
| Oct 16, 2026 | $511.06 | $512.21 | $497.4935 | $499.74 | 1.41M |
| Oct 15, 2026 | $514.91 | $517.6795 | $507.21 | $508.75 | 2.26M |
| Oct 14, 2026 | $490.45 | $502.935 | $487.54 | $498.50 | 2.09M |
| Oct 13, 2026 | $507.55 | $508.57 | $484.08 | $485.22 | 1.19M |
| Oct 12, 2026 | $512.44 | $514.80 | $506.00 | $507.00 | 952.75K |
| Oct 9, 2026 | $502.11 | $514.90 | $502.06 | $510.08 | 1.48M |
| Oct 8, 2026 | $503.14 | $507.87 | $498.90 | $503.25 | 1.49M |
| Oct 7, 2026 | $504.075 | $511.505 | $503.942 | $505.64 | 806.84K |
| Oct 6, 2026 | $505.00 | $507.41 | $496.325 | $502.31 | 775.07K |
| Oct 5, 2026 | $504.78 | $506.01 | $496.15 | $503.50 | 915.14K |
| Oct 2, 2026 | $509.50 | $509.50 | $499.95 | $504.73 | 939.66K |
| Oct 1, 2026 | $522.39 | $523.515 | $505.27 | $506.74 | 1.19M |
Latest VRTX news
The latest Smart Investors Daily articles mentioning VRTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VRTX research
Overview
Company profile and research snapshot.
Company profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $483.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 28, 2026 | UBS | Buy | — |
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 24, 2026
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm
SeekingAlpha · Oct 23, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow
2026-10-23. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.
Yahoo · Oct 23, 2026
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
BOSTON, October 23, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
